The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Prevention of progression: ixazomib/len/dex in high-risk SMM
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase 2 trial aimed to determine the progression-free survival and response rate of early therapeutic intervention in patients with high-risk smoldering multiple myeloma (SMM) using the combination of ixazomib, lenalidomide and dexamethasone. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
